Hamel Associates’s GSK GSK Stock Holding History

Hamel Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,280	Closed	-$205K	–	82
2016 Q4	$205K	Hold	4,280	–	–	0.11%	82
2016 Q3	$231K	Hold	4,280	–	–	0.12%	79
2016 Q2	$232K	Hold	4,280	–	–	0.12%	83
2016 Q1	$216K	Sell	4,280 -5,100	-54%	-$254K	0.11%	87
2015 Q4	$473K	Sell	9,380 -5,380	-36%	-$274K	0.3%	62
2015 Q3	$709K	Sell	14,760 -15,300	-51%	-$796K	0.5%	55
2015 Q2	$1.56M	Sell	30,060 -11,840	-28%	-$667K	1.03%	37
2015 Q1	$2.42M	Buy	41,900 +860	+2%	+$49.3K	1.6%	20
2014 Q4	$2.19M	Buy	41,040 +18,160	+79%	+$1.02M	1.42%	24
2014 Q3	$1.31M	Buy	22,880 +12,308	+116%	+$755K	0.88%	42
2014 Q2	$707K	Sell	10,572 -220	-2%	-$14.9K	0.47%	64
2014 Q1	$720K	Sell	10,792 -608	-5%	-$41.1K	0.5%	61
2013 Q4	$760K	Buy	+11,400	New	+$739K	0.53%	60

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hamel Associates's GSK Position: Q1 2017 in Review

Hamel Associates sold out of GSK (GSK) in Q1 2017, closing a stake of 4,280 shares — an estimated $205K sold.

Hamel Associates first reported a position in GSK in Q4 2013 and held it in 13 quarters. The position peaked at $2.42M in Q1 2015. 787 funds tracked by Wall St. Rank hold GSK as of Q1 2017.

Hamel Associates reported no remaining GSK position as of Q1 2017 after selling out during the quarter.
Hamel Associates sold 4,280 GSK shares in Q1 2017, an estimated $205K.
Hamel Associates first reported a position in GSK in Q4 2013 and held it in 13 quarters.
Hamel Associates's GSK position peaked at $2.42M in Q1 2015.
787 funds tracked by Wall St. Rank held GSK as of Q1 2017.

Based on Hamel Associates's 13F filing for Q1 2017, filed 9 May 2017.